Identification of the human liver cytochrome P450 isoenzymes responsible for the 5-methylhydroxylation of the novel anti-fibrotic drug AKF-PD

Xenobiotica

Volumn 41, Issue 10, 2011, Pages 844-850

  He, Xiaoai ^a   Luo, Xi ^b   Liu, Zhi ^c   Hu, Gaoyun ^b   Cheng, Zeneng ^b  

^a Central South University   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Hunan Tiger Xiangya RandD Company Ltd   (China)

Author keywords

AKF PD; human CYP; metabolism; microsomes; supersomes

Indexed keywords

5 METHYL 1 (3 FLUOROPHENYL) 2 (1H) PYRIDONE; ALPHA NAPHTHOFLAVONE; ANTIFIBROTIC AGENT; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DRUG METABOLITE; KETOCONAZOLE; OMEPRAZOLE; PYRIDONE DERIVATIVE; QUINIDINE; SULFAPHENAZOLE; UNCLASSIFIED DRUG; ZALCITABINE;

ANIMAL CELL; ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; LIVER MICROSOME; LIVER MICROSOME METABOLISM; NONHUMAN;

CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; ISOENZYMES; METABOLIC NETWORKS AND PATHWAYS; MICROSOMES, LIVER; PYRIDONES;

EID: 80052901740     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.589480     Document Type: Article

References (22)

1. Al-Bayati MA, Xie Y, Mohr FC, Margolin SB, Giri SN. (2002).Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. Biochem Pharmacol 64:517-525. (Pubitemid 34874855)
2. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. (1995).Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
3. Chen XP, Han XM, Jiang CH, Huang SL, Liu ZQ, Zhu B, Zhou G, Zhou HH. (2002).Phenotype distribution and gender-related differences of CYP2E1 activity in a Chinese population. Xenobiotica 32:1053-1062. (Pubitemid 35347012)
4. Cifuentes A, Valencia J, Sanz E, Sánchez MJ, Rodríguez- Delgado MA. (1997).Separation and quantitation of debrisoquine and 4-hydroxydebrisoquine in human urine by capillary electrophoresis and high-performance liquid chromatography. J Chromatogr A 778:389-396. (Pubitemid 27362238)
5. Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, Beaune P, Janezic S, Grant D, Meyer UA, Staib AH. (1996).Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 6:159-176. (Pubitemid 26153359)
6. Giri SN, Wang Q, Xie Y, Lango J, Morin D, Margolin SB, Buckpitt AR. (2002).Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. Biopharm Drug Dispos 23:203-211. (Pubitemid 34812311)
7. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. (1995).Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 125:779-785.
8. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. (1997).Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 25:853-862. (Pubitemid 27318604)
9. Landi MT, Sinha R, Lang NP, Kadlubar FF. (1999).Human cytochrome P4501A2. IARC Sci Publ 148:173-195.
10. Lasker JM, Wester MR, Aramsombatdee E, Raucy JL. (1998).Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 353:16-28. (Pubitemid 28373025)
11. Lehmann B, Boulieu R. (1995).Determination of midazolam and its unconjugated 1-hydroxy metabolite in human plasma by high-performance liquid chromatography. J Chromatogr B, Biomed Appl 674:138-142.
12. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951).Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
13. Maurel P. (1998).Drug metabolizing enzymes. Curr Opin Crit Care, 4, 213-18. (Pubitemid 128353493)
14. Newton DJ, Wang RW, Lu AY. (1995).Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
15. Omura T, Sato R. (1964).The carbon monoxide-binding pigment of liver microsomes. i. evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
16. Ou-Yang DS, Huang SL, Xie HG, Wang CY, Zhou HH. (1998).Use of caffeine as a probe for rapid determination of cytochrome P-450 CYP1A2 activity in humans. Zhongguo Yao Li Xue Bao 19:44-46.
17. Raghu G, Johnson WC, Lockhart D, Mageto Y. (1999).Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 159:1061-1069. (Pubitemid 29202536)
18. Rendic S, Di Carlo FJ. (1997).Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413-580. (Pubitemid 27293618)
19. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. (1994).Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423. (Pubitemid 24229655)
20. von Bahr C, Groth CG, Jansson H, Lundgren G, Lind M, Glaumann H. (1980).Drug metabolism in human liver in vitro: establishment of a human liver bank. Clin Pharmacol Ther 27:711-725. (Pubitemid 10072956)
21. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. (1998).In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 55:113-122. (Pubitemid 28006177)
22. Gahl WA, Brantly M, Troendle J, Avila NA, Padua A, Montalvo C, Cardona H, Calis KA, Gochuico B. (2002).Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 76:234-242. (Pubitemid 35034557)